ReviewCurrent drug targets2013
Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins.
Review in Current drug targets, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04436549 (Clinical and Pathological Correlations in Chronic Venous Disease), which is not on this map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical and Pathological Correlations in Chronic Venous Disease
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 95 citations in OpenAlex.
- Protease activity as a prognostic factor for wound healing in venous leg ulcers.The Cochrane database of systematic reviews · 2018Pooled it
- The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs.Drug design, development and therapy · 2014Trial
- Decreased PGE₂ content reduces MMP-1 activity and consequently increases collagen density in human varicose vein.PloS one · 2014Trial
- Aberrant Uteroplacental and Vascular Signaling and Remodeling by Matrix Metalloproteinases in Pregnancy-Related Hypertension and Preeclampsia.Biomolecules · 2026Review
- Local and Systemic Endothelial Damage in Patients with CEAP C2 Chronic Venous Insufficiency: Role of Mesoglycan.International journal of molecular sciences · 2025Article
- Cosmeceutical application of extracts from the flowers, stems, and leaves ofFrontiers in pharmacology · 2025Article
- Hematohidrosis: A Rare Case of Blood Sweating.Cardiovascular & hematological disorders drug targets · 2025Article
- Key Regulators of Angiogenesis and Inflammation Are Dysregulated in Patients with Varicose Veins.International journal of molecular sciences · 2024Article
- Factors Influencing Venous Remodeling in the Development of Varicose Veins of the Lower Limbs.International journal of molecular sciences · 2024Review
- Relationship between internal diameter and vasoconstriction in human varicose veins.Journal of smooth muscle research = Nihon Heikatsukin Gakkai kikanshi · 2024Article
- Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies.Molecular cancer · 2023Review
- The multifaceted roles of matrix metalloproteinases in lung cancer.Frontiers in oncology · 2023Review
- TNFα blockade reverses vascular and uteroplacental matrix metalloproteinases imbalance and collagen accumulation in hypertensive pregnant rats.Biochemical pharmacology · 2021Article
- Article
- Intense remodeling of extracellular matrix within the varicose vein: the role of gelatinases and vascular endothelial growth factor.Irish journal of medical science · 2021Article
- Role of mechanosignaling on pathology of varicose vein.Biophysical reviews · 2021Review
- Metalloproteinases in Inflammatory Bowel Diseases.Journal of inflammation research · 2021Review
- Mechanisms of Lower Extremity Vein Dysfunction in Chronic Venous Disease and Implications in Management of Varicose Veins.Vessel plus · 2021Article
- Compression therapy in venous diseases: physical assumptions and clinical effects.Postepy dermatologii i alergologii · 2020Review
- The Causal Effects of Blood Iron and Copper on Lipid Metabolism Diseases: Evidence from Phenome-Wide Mendelian Randomization Study.Nutrients · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Varicose veins (VVs) are a common venous disease of the lower extremity characterized by incompetent valves, venous reflux, and dilated and tortuous veins. If untreated, VVs could lead to venous thrombosis, thrombophlebitis and chronic venous leg ulcers. Various genetic, hormonal and environmental factors may lead to structural changes in the vein valves and make them incompetent, leading to venous reflux, increased venous pressure and vein wall dilation. Prolonged increases in venous pressure and vein wall tension are thought to increase the expression/activity of matrix metalloproteinases (MMPs). Members of the MMPs family include collagenases, gelatinases, stromelysins, matrilysins, membrane- type MMPs and others. MMPs are known to degrade various components of the extracellular matrix (ECM). MMPs may also affect the endothelium and vascular smooth muscle, causing changes in the vein relaxation and contraction mechanisms. Endothelial cell injury also triggers leukocyte infiltration, activation and inflammation, which lead to further vein wall damage. The vein wall dilation and valve dysfunction, and the MMP activation and superimposed inflammation and fibrosis would lead to progressive venous dilation and VVs formation. Surgical ablation is an effective treatment for VVs, but may be associated with high recurrence rate, and other less invasive approaches that target the cause of the disease are needed. MMP inhibitors including endogenous tissue inhibitors (TIMPs) and pharmacological inhibitors such as zinc chelators, doxycycline, batimastat and marimastat, have been used as diagnostic and therapeutic tools in cancer, autoimmune and cardiovascular disease. However, MMP inhibitors may have side effects especially on the musculoskeletal system. With the advent of new genetic and pharmacological tools, specific MMP inhibitors with fewer undesirable effects could be useful to retard the progression and prevent the recurrence of VVs.
Indexed as
Identifiers
23316963PMC3584231W2016616010What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.